olaparib
NICE fail to recommend AstraZeneca’s cancer drug Olaparib on cost effectiveness basis
November 9, 2018Medical Communications, Sales and Marketing AstraZeneca, NHS, NICE, UK, olaparib, pharma
Britain’s cost effectiveness body the National Institute of Health and Care Excellence (NICE) has chosen not to recommend AstraZeneca’s Olaparib …
AZ’s Lynparza gets prostate cancer breakthrough status
January 28, 2016Sales and Marketing AstraZeneca, Breakthrough Therapy Designation, FDA, lynparza, olaparib, prostate cancer
AstraZeneca’s Lynparza has been granted breakthrough therapy designation by the FDA as a monotherapy for the treatment of a specific …
NICE recommends AstraZeneca’s Lynparza after price reduction
December 11, 2015Medical Communications, Sales and Marketing AstraZeneca, NICE, fallopian tube cancer, lynparza, olaparib, ovarian cancer, peritoneal cancer
NICE has recommended AstraZeneca’s Lynparza for maintenance treatment of relapsed ovarian, fallopian tube and peritoneal cancer. In draft guidance the …
NICE Lynparza rejection labelled ‘hard to understand’
June 2, 2015Sales and Marketing AstraZeneca, NICE, lynparza, olaparib
AstraZeneca has appealed to the government to put ‘urgent transitional measures’ in place to make sure patients can access innovative …
AstraZeneca drops CDF application
January 12, 2015Sales and Marketing AstraZeneca, CDF, Cancer, NHS, NICE, lynparza, olaparib
AstraZeneca has withdrawn its application for its drug Lynparza to be on the Cancer Drugs Fund (CDF), citing concerns with …
AstraZeneca ovarian cancer drug approved in Europe
December 18, 2014Sales and Marketing AstraZeneca, BRCA, Cambridge, Cancer, FDA, lynparza, olaparib, ovarian
The European Commission has approved AstraZeneca’s Lynparza for the treatment of advanced BRCA-mutated ovarian cancer. Lynparza (olaparib) has been approved …
AZ oncology drug a ‘Phoenix from the flames’
October 27, 2014Sales and Marketing AstraZeneca, CHMP, EC, lynparza, olaparib, oncology
As the possibility of a deal with Pfizer fades, AstraZeneca is continuing its argument for independence as a key cancer …
FDA rejects olaparib
June 27, 2014Sales and Marketing AstraZeneca, Cancer, FDA, PARP, adp, olaparib
AstraZeneca has been dealt a blow by a key advisory committee to the US Food and Drug Administration, which has …
AstraZeneca faces olaparib questions
June 24, 2014Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, FDA, olaparib, ovarian
AstraZeneca is facing questions from US regulators over the efficacy of one of its most promising late-stage treatments. Olaparib is …
AstraZeneca begins olaparib programme
September 4, 2013Sales and Marketing AstraZeneca, olaparib, ovarian cancer
AstraZeneca has begun recruitment in its Phase III programme for olaparib, a potential first-in-class oral poly ADP ribose polymerase (PARP) …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
